ea0089o4 | Other | NANETS2022
Alaklabi Sabah
, Maguire Orla
, Zhang Yali
, Chow Jacky
, Wang Jiamin
, Minderman Hans
, Iyer Renuka
Background: Lanreotide is clinically effective in advanced neuroendocrine tumors (NETs). The inhibitory effect of lanreotide on tumor cells proliferation is due to binding to somatostatin receptors (SSTR1-5). It has been demonstrated that immune cells express SSTR1-5 differentially. The exact effect of somatostatin analogs (SSAs) on T cell function is not understood.Methods: In vitro and in vivo effects of lanreotide on immune cells wer...